New hope for aggressive brain tumors: drugs delivered directly to the brain
NCT ID NCT01386710
First seen Jun 02, 2026 · Last updated Jun 02, 2026
Summary
This study tests a new way to deliver two cancer drugs (bevacizumab and carboplatin) directly to the brain through an artery for people with recurrent glioblastoma or anaplastic astrocytoma. The goal is to see if repeated doses are safe and can shrink tumors or slow their growth better than standard intravenous therapy. The trial involves 54 adults whose tumors have come back after initial treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lenox Hill Brain Tumor Center
New York, New York, 10075, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.